1. Burt LM, Shrieve DC, Tward JD. Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. Adv Radiat Oncol 2018; 3: 170-180.
2.
Siegel RL, Miller KD, Wagle NS et al. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17-48.
3.
Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005; 294: 1233-1239.
4.
Krauss D, Kestin L, Ye H et al. Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1064-1071.
5.
Pasalic D, Kuban DA, Allen PK et al. Dose escalation for prostate adenocarcinoma: A long-term update on the outcomes of a phase 3, single institution randomized clinical trial. Int J Radiat Oncol Biol Phys 2019; 104: 790-797.
6.
Krauss DJ, Karrison T, Martinez AA et al. Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: Results of a phase III multi-institutional trial. J Clin Oncol 2023; 41: 3203-3216.
7.
Michalski JM, Winter KA, Prestidge BR et al. Effect of brachytherapy with external beam radiation therapy versus brachytherapy alone for intermediate-risk prostate cancer: NRG Oncology RTOG 0232 randomized clinical trial. J Clin Oncol 2023; 41: 4035-4044.
8.
Oh J, Tyldesley S, Pai H et al. An updated analysis of the survival endpoints of ASCENDE-RT. Int J Radiat Oncol Biol Phys 2023; 115: 1061-1070.
9.
Liu Y, Nickleach DC, Zhang C et al. Carrying out streamlined routine data analyses with reports for observational studies: introduction to a series of generic SAS (®) macros. F1000Res 2018; 7: 1955.
10.
Schaeffer EM, Srinivas S, Adra N et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023; 21: 1067-1096.
11.
Merrick GS, Galbreath RW, Butler WM et al. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer. Cancer 2007; 110: 289-296.
12.
Ho AY, Burri RJ, Cesaretti JA et al. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2009; 75: 16-22.
13.
Stock RG, Yalamanchi S, Hall SJ et al. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation. J Urol 2010; 183: 546-550.
14.
Merrick GS, Wallner KE, Butler WM et al. 20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial. Int J Radiat Oncol Biol Phys 2012; 82: e449-455.
15.
Bittner N, Merrick GS, Butler WM et al. Gleason score 7 prostate cancer treated with interstitial brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: is the primary pattern on needle biopsy prognostic? Brachytherapy 2013; 12: 14-18.
16.
Tran AT, Mandall P, Swindell R et al. Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy. Radiother Oncol 2013; 109: 235-240.
17.
Merrick GS, Wallner KE, Galbreath RW et al. Is supplemental external beam radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable intermediate-risk disease? Brachytherapy 2016; 15: 79-84.
18.
Nguyen PL, Alibhai SM, Basaria S et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67: 825-836.
19.
Keyes M, Merrick G, Frank SJ et al. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy – a systematic literature review. Brachytherapy 2017; 16: 245-265.
20.
Mohiuddin JJ, Narayan V, Venigalla S et al. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer. Brachytherapy 2019; 18: 322-331.
21.
Jackson WC, Hartman HE, Dess RT et al. Addition of androgen-deprivation therapy or brachytherapy boost to external beam radiotherapy for localized prostate cancer: A network meta-analysis of randomized trials. J Clin Oncol 2020; 38: 3024-3031.
22.
Andruska N, Agabalogun T, Fischer-Valuck BW et al. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy. Brachytherapy 2022; 21: 617-625.
23.
Andruska N, Fischer-Valuck BW, Carmona R, Agabalogun T, Brenneman RJ, Gay HA, et al. Outcomes of patients with unfavorable intermediate-risk prostate cancer treated with external-beam radiotherapy versus brachytherapy alone. J Natl Compr Canc Netw 2022; 20: 343-50.e4
24.
Mendez LC, Martell K, Warner A et al. Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis. Radiother Oncol 2020; 150: 195-200.
25.
Smile TD, Tom MC, Halima A et al. (125)I Interstitial brachytherapy with or without androgen deprivation therapy among unfavorable-intermediate and high-risk prostate cancer. Brachytherapy 2022; 21: 85-93.
26.
Spratt DE, Zhang J, Santiago-Jiménez M et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. J Clin Oncol 2018; 36: 581-590.
27.
Hofman MS, Lawrentschuk N, Francis RJ et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395: 1208-1216.
